Own the gold standard ✨ in financial data & analytics

Subscribe for $2
Overview
Profile
Tasly Pharmaceutical Group Co - Stock

Tasly Pharmaceutical Group Co Stock

600535.SS
CNE000001C81

Price

12.90
Today +/-
+0
Today %
+0 %
P

Tasly Pharmaceutical Group Co Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Tasly Pharmaceutical Group Co, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Tasly Pharmaceutical Group Co from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Tasly Pharmaceutical Group Co’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Tasly Pharmaceutical Group Co. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Tasly Pharmaceutical Group Co’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Tasly Pharmaceutical Group Co’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Tasly Pharmaceutical Group Co’s growth potential.

Tasly Pharmaceutical Group Co Revenue, EBIT and net profit per share

DateTasly Pharmaceutical Group Co RevenueTasly Pharmaceutical Group Co EBITTasly Pharmaceutical Group Co Net Income
2026e10.15 B undefined1.79 B undefined1.49 B undefined
2025e9.61 B undefined1.71 B undefined1.39 B undefined
2024e9.12 B undefined1.61 B undefined1.24 B undefined
20238.67 B undefined1.47 B undefined1.07 B undefined
20228.64 B undefined1.32 B undefined-264.24 M undefined
20217.95 B undefined2.56 B undefined2.36 B undefined
202013.58 B undefined1.45 B undefined1.13 B undefined
201919 B undefined1.96 B undefined1 B undefined
201817.99 B undefined2.44 B undefined1.55 B undefined
201716.09 B undefined2.09 B undefined1.38 B undefined
201613.95 B undefined1.7 B undefined1.18 B undefined
201513.23 B undefined2 B undefined1.48 B undefined
201412.58 B undefined2.01 B undefined1.37 B undefined
201311.11 B undefined1.54 B undefined1.1 B undefined
20129.34 B undefined1.16 B undefined850 M undefined
20116.57 B undefined720 M undefined611 M undefined
20104.65 B undefined590 M undefined450 M undefined
20093.99 B undefined422 M undefined317 M undefined
20083.43 B undefined388 M undefined256 M undefined
20072.82 B undefined267 M undefined186 M undefined
20062.42 B undefined306 M undefined209 M undefined
20051.47 B undefined277 M undefined194 M undefined
20041.3 B undefined240 M undefined171 M undefined

Tasly Pharmaceutical Group Co Stock Ratios

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (B)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (B)EBIT (B)EBIT MARGIN (%)NET INCOME (B)NET INCOME GROWTH (%)DIV. ()DIV. GROWTH (%)SHARES (B)DOCUMENTS
2000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024e2025e2026e
0.390.690.931.061.31.472.422.823.433.994.656.579.3411.1112.5813.2313.9516.0917.991913.587.958.648.679.129.6110.15
-74.7435.7713.5523.3012.6065.3516.3021.8216.2816.5041.2342.2118.8913.235.175.4215.4111.785.60-28.54-41.438.630.435.185.345.65
78.3276.0676.7771.0259.6052.6634.2832.7432.4732.0333.0229.2733.5836.3537.4138.7136.4936.2436.1931.2840.6266.2763.5666.73---
0.310.520.710.750.780.770.830.921.121.281.541.923.144.044.715.125.095.836.515.945.525.275.495.79000
0.10.140.160.180.240.280.310.270.390.420.590.721.161.542.0121.72.092.441.961.452.561.321.471.611.711.79
25.2620.4416.9917.3318.4318.8912.629.4711.3010.5712.6810.9612.4313.8616.0015.1512.1912.9913.5510.3310.6532.2115.3216.9917.6817.7517.66
0.080.10.120.140.170.190.210.190.260.320.450.610.851.11.371.481.181.381.5511.132.36-0.261.071.241.391.49
-28.7514.5619.4921.2813.457.73-11.0037.6323.8341.9635.7839.1229.1824.598.11-20.4917.0912.20-35.2112.49109.41-111.20-505.6815.3112.397.56
---------------------------
---------------------------
0.940.941.281.281.281.281.281.371.371.371.371.451.451.451.451.511.511.511.511.511.51.51.471.49000
- - - - - - - - - - - - - - - - - - - - - - - - - - -
Details

Keystats

ⓘ

Revenue and Growth

The Tasly Pharmaceutical Group Co Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Tasly Pharmaceutical Group Co is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Tasly Pharmaceutical Group Co provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Tasly Pharmaceutical Group Co's financial health and stability.

Assets

Tasly Pharmaceutical Group Co's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Tasly Pharmaceutical Group Co must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Tasly Pharmaceutical Group Co after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Tasly Pharmaceutical Group Co's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (B)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (B)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (B)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (B)CASH FLOW FROM OTHER FINANCING ACTIVITIES (B)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (B)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
2001200220032004200520062007200820092010201120122013201420152016201720182019202020212022
0000000000000000000000
0000000000000000000000
0000000000000000000000
-365-437-468-431-389-401-446-506-636-662-792-2,020-2,364-2,924-3,316-3,681-3,799-4,109-4,195-3,924-4,156-4,224
0000000000000000000000
0000000000000000000000
-148-178-167-214-254-235-284-367-333-432-581-846-1,181-1,241-1,343-1,330-1,538-1,700-1,255-1,112-1,007-1,105
0.080.210.060.20.210.140.220.260.40.40.140.450.350.620.341.15-0.81.491.681.792.82.29
-119-126-328-369-296-255-205-114-116-166-422-554-809-754-737-524-511-780-730-408-571-403
-118-126-391-479-387-141-255-179-378-163-319-425-922-566-910-653-1,366-641-492865-42-1,265
00-0.06-0.11-0.090.11-0.05-0.07-0.2600.10.13-0.110.19-0.17-0.13-0.850.140.241.270.53-0.86
0000000000000000000000
0.13-0.230.30.130.21-0.16-0.480.070.3100.57-0.111.311.27-0.030.593.361.28-1.55-1.37-1.20.48
0000000000000000000000
0.050.480.250.040.33-0.02-0.230.010.110.78-0.03-0.530.470.070.29-0.232.380.83-2.39-2.31-2.48-0.24
00.730.050.020.240.250.370.140.051.03-0.230.02-0.54-0.50.95-0.21-0.050.410.06-0.14-0.67-0.16
-83-20-104-102-112-120-126-207-246-247-369-446-295-703-635-616-930-860-903-799-610-553
0.621.380.610.621.020.750.691.221.52.51.292.813.784.94.716.434.768.985.937.168.248.43
-35.680.1-269.7-166.3-81.4-114.818145.7283.6229-287.5-103-464.8-138.1-397.8629-1,307.2713.7949.31,382.42,229.441,881.69
0000000000000000000000

Tasly Pharmaceutical Group Co stock margins

The Tasly Pharmaceutical Group Co margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Tasly Pharmaceutical Group Co. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Tasly Pharmaceutical Group Co.

  • 3 years

  • 5 years

  • 10 years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Tasly Pharmaceutical Group Co's sales revenue. A higher gross margin percentage indicates that the Tasly Pharmaceutical Group Co retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Tasly Pharmaceutical Group Co's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Tasly Pharmaceutical Group Co's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Tasly Pharmaceutical Group Co's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Tasly Pharmaceutical Group Co. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Tasly Pharmaceutical Group Co's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Tasly Pharmaceutical Group Co Margin History

Tasly Pharmaceutical Group Co Gross marginTasly Pharmaceutical Group Co Profit marginTasly Pharmaceutical Group Co EBIT marginTasly Pharmaceutical Group Co Profit margin
2026e66.74 %17.66 %14.71 %
2025e66.74 %17.75 %14.45 %
2024e66.74 %17.68 %13.54 %
202366.74 %17 %12.35 %
202263.56 %15.33 %-3.06 %
202166.27 %32.21 %29.66 %
202040.62 %10.65 %8.29 %
201931.28 %10.33 %5.27 %
201836.19 %13.55 %8.59 %
201736.24 %12.99 %8.56 %
201636.49 %12.19 %8.43 %
201538.71 %15.15 %11.18 %
201437.41 %16 %10.88 %
201336.35 %13.86 %9.88 %
201233.58 %12.43 %9.1 %
201129.27 %10.96 %9.3 %
201033.02 %12.68 %9.67 %
200932.03 %10.57 %7.94 %
200832.47 %11.3 %7.45 %
200732.74 %9.47 %6.6 %
200634.28 %12.62 %8.62 %
200552.66 %18.89 %13.23 %
200459.6 %18.43 %13.13 %

Tasly Pharmaceutical Group Co Stock Sales Revenue, EBIT, Earnings per Share

The Tasly Pharmaceutical Group Co earnings per share therefore indicates how much revenue Tasly Pharmaceutical Group Co has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Tasly Pharmaceutical Group Co earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Tasly Pharmaceutical Group Co's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Tasly Pharmaceutical Group Co’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Tasly Pharmaceutical Group Co's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Tasly Pharmaceutical Group Co Revenue, EBIT and net profit per share

DateTasly Pharmaceutical Group Co Sales per ShareTasly Pharmaceutical Group Co EBIT per shareTasly Pharmaceutical Group Co Earnings per Share
2026e6.8 undefined0 undefined1 undefined
2025e6.43 undefined0 undefined0.93 undefined
2024e6.11 undefined0 undefined0.83 undefined
20235.81 undefined0.99 undefined0.72 undefined
20225.88 undefined0.9 undefined-0.18 undefined
20215.29 undefined1.7 undefined1.57 undefined
20209.04 undefined0.96 undefined0.75 undefined
201912.56 undefined1.3 undefined0.66 undefined
201811.89 undefined1.61 undefined1.02 undefined
201710.64 undefined1.38 undefined0.91 undefined
20169.22 undefined1.12 undefined0.78 undefined
20158.74 undefined1.32 undefined0.98 undefined
20148.7 undefined1.39 undefined0.95 undefined
20137.68 undefined1.07 undefined0.76 undefined
20126.46 undefined0.8 undefined0.59 undefined
20114.54 undefined0.5 undefined0.42 undefined
20103.41 undefined0.43 undefined0.33 undefined
20092.92 undefined0.31 undefined0.23 undefined
20082.51 undefined0.28 undefined0.19 undefined
20072.06 undefined0.2 undefined0.14 undefined
20061.9 undefined0.24 undefined0.16 undefined
20051.15 undefined0.22 undefined0.15 undefined
20041.02 undefined0.19 undefined0.13 undefined

Tasly Pharmaceutical Group Co business model

Tasly Pharmaceutical Group Co is one of the most popular companies on Eulerpool.com.

Tasly Pharmaceutical Group Co valuation based on historical P/E ratio, EBIT, and P/S ratio.

Tasly Pharmaceutical Group Co shares outstanding

The number of shares was Tasly Pharmaceutical Group Co in 2023 — This indicates how many shares 1.494 B is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Tasly Pharmaceutical Group Co earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Tasly Pharmaceutical Group Co's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Tasly Pharmaceutical Group Co’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Tasly Pharmaceutical Group Co's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Tasly Pharmaceutical Group Co Stock splits

In Tasly Pharmaceutical Group Co's history, there have been no stock splits.

Tasly Pharmaceutical Group Co Stock Dividend

In 2023, Tasly Pharmaceutical Group Co paid a dividend amounting to 0.33 CNY. Dividend means that Tasly Pharmaceutical Group Co distributes a portion of its profits to its owners.

  • 3 years

  • 5 years

  • 10 years

  • Max

Dividend
Dividend (Estimate)
Details

Dividend

ⓘ

Dividend Overview

The dividend per year chart for Tasly Pharmaceutical Group Co provides a comprehensive view of the annual dividends distributed to shareholders. Analyze the trend to understand the consistency and growth in dividend payouts over the years.

Interpretation and Use

A consistent or increasing trend in dividends can indicate the company's profitability and financial health. Investors can use this data to identify Tasly Pharmaceutical Group Co’s potential for long-term investment and income generation through dividends.

Investment Strategy

Incorporate the dividend data in evaluating Tasly Pharmaceutical Group Co's overall performance. A thorough analysis, considering other financial aspects, will help in making informed investment decisions for optimal capital growth and income generation.

Tasly Pharmaceutical Group Co Dividend History

DateTasly Pharmaceutical Group Co Dividend
2026e0.33 undefined
2025e0.33 undefined
2024e0.33 undefined
20230.33 undefined
20220.33 undefined
20210.33 undefined
20200.33 undefined
20190.3 undefined
20180.29 undefined
20170.4 undefined
20160.3 undefined
20150.28 undefined
20140.25 undefined
20130.07 undefined
20120.25 undefined
20110.21 undefined
20100.14 undefined
20090.14 undefined
20080.11 undefined
20070.06 undefined
20060.07 undefined
20050.07 undefined
20040.07 undefined

Tasly Pharmaceutical Group Co Stock Payout Ratio

In 2023, Tasly Pharmaceutical Group Co had a payout ratio of 36.82%. The payout ratio indicates the percentage of the company's profits that Tasly Pharmaceutical Group Co distributes as dividends.

  • 3 years

  • 5 years

  • 10 years

  • Max

Payout ratio
Details

Payout ratio

ⓘ

What is Yearly Payout Ratio?

The yearly payout ratio for Tasly Pharmaceutical Group Co represents the proportion of earnings paid out as dividends to shareholders. It is an indicator of the company's financial health and stability, illustrating how much profit is being returned to investors versus being reinvested back into the company.

How to Interpret the Data

A lower payout ratio for Tasly Pharmaceutical Group Co could mean that the company is reinvesting more into its growth, whereas a higher ratio indicates more earnings are being distributed as dividends. Investors seeking regular income might prefer companies with a higher payout ratio, while those looking for growth may opt for companies with a lower ratio.

Using the Data for Investments

Evaluate Tasly Pharmaceutical Group Co's payout ratio in conjunction with other financial metrics and performance indicators. A sustainable payout ratio, coupled with strong financial health, can indicate a reliable dividend payout. However, a very high ratio might suggest the company is not sufficiently reinvesting in its future growth.

Tasly Pharmaceutical Group Co Payout Ratio History

DateTasly Pharmaceutical Group Co Payout ratio
2026e33.79 %
2025e30.6 %
2024e33.95 %
202336.82 %
2022-183.33 %
202121.02 %
202044 %
201945.45 %
201828.01 %
201743.96 %
201638.46 %
201528.43 %
201426.32 %
20139.39 %
201242.37 %
201151.02 %
201043.3 %
200962.13 %
200856.37 %
200744.71 %
200641.88 %
200544.67 %
200451.54 %
Unfortunately, there are currently no price targets and forecasts available for Tasly Pharmaceutical Group Co.

Tasly Pharmaceutical Group Co Earnings Surprises

DateEPS EstimateEPS ActualQuarterly report
3/31/20240.15 0.2  (30.43 %)2024 Q1
12/31/20230.16 0.03  (-83.99 %)2023 Q4
9/30/20230.23 0.22  (-5.29 %)2023 Q3
6/30/20230.28 0.29  (3.96 %)2023 Q2
3/31/20230.23 0.18  (-23.81 %)2023 Q1
12/31/20220.58 0.05  (-91.39 %)2022 Q4
9/30/20220.24 0.05  (-78.94 %)2022 Q3
6/30/20220.13 0.1  (-24.6 %)2022 Q2
3/31/20220.24 -0.37  (-251.9 %)2022 Q1
12/31/20210.08 0.58  (631.4 %)2021 Q4
1
2
3
4
5
...
7

Eulerpool ESG Scorecard© for the Tasly Pharmaceutical Group Co stock

Eulerpool World ESG Rating (EESG©)

71/ 100

🌱 Environment

79

👫 Social

63

🏛️ Governance

69

Environment

Scope 1 - Direct Emissions
—
Scope 2 - Indirect emissions from purchased energy
—
Scope 3 - Indirect emissions within the value chain
—
Total CO₂ emissions
—
CO₂ reduction strategy
✅
Coal energy
❌
Nuclear power
❌
Animal experiments
✅
Fur & Leather
—
Pesticides
—
Palm Oil
—
Tobacco
❌
Genetically modified organisms
❌
Climate concept
—
Sustainable forestry
—
Recycling regulations
❌
Environmentally friendly packaging
✅
Hazardous substances
✅
Fuel consumption and efficiency
❌
Water consumption and efficiency
✅

Social

Percentage of female employees49.82
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content❌
Alcohol❌
Weapons—
Firearms
❌
Gambling❌
Military contracts❌
Human rights concept✅
Privacy concept—
Occupational health and safety✅
Catholic✅

Governance (Corporate Governance)

Environmental reporting✅
Stakeholder Engagement❌
Call Back Policies❌
Antitrust law❌

Kontaktformular an uns. The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Tasly Pharmaceutical Group Co Stock Shareholders

%
Name
Stocks
Change
Date
45.75 % Tasly Holding Group Co., Ltd.683,481,52409/30/2023
1.95 % Tianjin Heyue Technology Development Partnership (LP)29,175,35009/30/2023
1.57 % Fullgoal Fund Management Co., Ltd.23,423,4094,600,0009/30/2023
0.90 % Liu (Shaoluan)13,416,70509/30/2023
0.84 % Tianjin Kangshun Technology Development Partnership (LP)12,503,72209/30/2023
0.61 % Liu (Wenhua)9,092,366559,7439/30/2023
0.58 % Yang (Wei)8,633,4408,633,4409/30/2023
0.55 % Dacheng Fund Management Co., Ltd.8,213,006-176,5009/30/2023
0.54 % China Southern Asset Management Co. Ltd.8,098,306-202,3009/30/2023
0.52 % Yinhua Fund Management Co., Ltd.7,747,506-298,17412/31/2023
1
2
3
4
5
...
10

Tasly Pharmaceutical Group Co Executives and Management Board

Ms. Naifeng Wu69
Tasly Pharmaceutical Group Co Director
Compensation 4.62 M
Mr. Yonghong Zhu58
Tasly Pharmaceutical Group Co Director (since 2013)
Compensation 3.42 M
Mr. Kaijing Yan43
Tasly Pharmaceutical Group Co Chairman of the Board (since 2015)
Compensation 2.85 M
Mr. Jie Yu47
Tasly Pharmaceutical Group Co Deputy General Manager, Secretary of the Board
Compensation 2.49 M
Mr. Jing Su60
Tasly Pharmaceutical Group Co General Manager, Director (since 2020)
Compensation 2.43 M
1
2
3

Tasly Pharmaceutical Group Co stock: Frequently Asked Questions

What is the P/E ratio of Tasly Pharmaceutical Group Co 2024?

The Tasly Pharmaceutical Group Co P/E ratio is 15.6.

What is the P/S ratio of Tasly Pharmaceutical Group Co 2024?

The Tasly Pharmaceutical Group Co P/S ratio is 2.11.

What is the AlleAktien quality score of Tasly Pharmaceutical Group Co?

The AlleAktien quality score for Tasly Pharmaceutical Group Co is 3/10.

What is the revenue of Tasly Pharmaceutical Group Co 2024?

The expected Tasly Pharmaceutical Group Co revenue is 9.12 B CNY.

How high is the profit of Tasly Pharmaceutical Group Co 2024?

The expected Tasly Pharmaceutical Group Co profit is 1.24 B CNY.

What is the business model of Tasly Pharmaceutical Group Co

No history available for Tasly Pharmaceutical Group Co.

What is the Tasly Pharmaceutical Group Co dividend?

Tasly Pharmaceutical Group Co pays a dividend of 0.33 CNY distributed over payouts per year.

How often does Tasly Pharmaceutical Group Co pay dividends?

The dividend cannot currently be calculated for Tasly Pharmaceutical Group Co or the company does not pay out a dividend.

What is the Tasly Pharmaceutical Group Co ISIN?

The ISIN of Tasly Pharmaceutical Group Co is CNE000001C81.

What is the Tasly Pharmaceutical Group Co ticker?

The ticker of Tasly Pharmaceutical Group Co is 600535.SS.

How much dividend does Tasly Pharmaceutical Group Co pay?

Over the past 12 months, Tasly Pharmaceutical Group Co paid a dividend of 0.33 CNY . This corresponds to a dividend yield of about 2.56 %. For the coming 12 months, Tasly Pharmaceutical Group Co is expected to pay a dividend of 0.33 CNY.

What is the dividend yield of Tasly Pharmaceutical Group Co?

The current dividend yield of Tasly Pharmaceutical Group Co is 2.56 %.

When does Tasly Pharmaceutical Group Co pay dividends?

Tasly Pharmaceutical Group Co pays a quarterly dividend. This is distributed in the months of July, July, June, June.

How secure is the dividend of Tasly Pharmaceutical Group Co?

Tasly Pharmaceutical Group Co paid dividends every year for the past 23 years.

What is the dividend of Tasly Pharmaceutical Group Co?

For the upcoming 12 months, dividends amounting to 0.33 CNY are expected. This corresponds to a dividend yield of 2.52 %.

In which sector is Tasly Pharmaceutical Group Co located?

Tasly Pharmaceutical Group Co is assigned to the 'Health' sector.

Wann musste ich die Aktien von Tasly Pharmaceutical Group Co kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Tasly Pharmaceutical Group Co from 5/29/2024 amounting to 0.33 CNY, you needed to have the stock in your portfolio before the ex-date on 5/29/2024.

When did Tasly Pharmaceutical Group Co pay the last dividend?

The last dividend was paid out on 5/29/2024.

What was the dividend of Tasly Pharmaceutical Group Co in the year 2023?

In the year 2023, Tasly Pharmaceutical Group Co distributed 0.33 CNY as dividends.

In which currency does Tasly Pharmaceutical Group Co pay out the dividend?

The dividends of Tasly Pharmaceutical Group Co are distributed in CNY.

Other fundamentals and analyses of Tasly Pharmaceutical Group Co in the deep dive.

Our stock analysis for Tasly Pharmaceutical Group Co Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Tasly Pharmaceutical Group Co Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.